BiologicsSpineTop Stories

Xlife Sciences and curasan form joint venture company to research biosurgical treatment therapies

Kleinostheim, Germany, 21 March 2022, OrthoSpineNews

Xlife Sciences AG (SIX: XLS) and curasan AG, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery, have formed the joint biosurgical company Novaxomx. The joint venture, Novaxomx GmbH, is based at the Eisenberg campus of the University Hospital Jena (Germany) and focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration.

Novaxomx’ primary goal is to optimize biomimetic osteoconductive carrier materials by biologizing them with growth- and healing-promoting substances to improve biofunctionality and availability in regenerative processes such as non-union or delayed non-union fractures or bone fusion after spinal fusion procedures. Other applications include the treatment of chronic osteomyelitis, rheumatoid arthritis, or periodontal bone loss.

The research and development approach of Novaxomx is based on the patented “exosome” technology of the Xlife Sciences project company Lysatpharma. Exosomes are bioactive nanovesicles secreted from human stem cells or derived from autologous platelets. They are introduced with the carrier materials and enable intercellular communication, which is crucial for regenerative processes in the human body. Lysatpharma uses extracellular vesicles obtained from the surplus production of high-quality, tested blood products. These blood products are continuously supplied by certified blood banks for clinical primary care.

Frank Plöger, Chief Scientific Officer of Xlife Sciences and also Managing Director of Lysatpharma, says: “Lysatpharma’s first approach in the animal model for rheumatoid arthritis was very successful. The human extracellular vesicles led to a reduction in inflammation without any side effects. Our results and the scientifically proven regenerative efficacy of exosomes are promising prerequisites for their use in musculoskeletal surgery or bone and tissue regeneration. The establishment of a joint venture with Curasan, one of the leading providers in this segment, is therefore an important milestone for Xlife Sciences.”

Florian Früh, Managing Director of Novaxomx GmbH adds: “Current therapeutic options for musculoskeletal diseases, especially non-union or delayed non-union fractures and pseudarthrosis, are limited and represent an enormous challenge for patients, surgeons and our healthcare system alike. We are focusing on new solutions by taking a cross-indication and interdisciplinary approach to develop disruptive, biosurgical products that fundamentally improve healing chances for these indications.”

“The biological refinement of our clinically proven scaffold materials for bone and tissue regeneration with nanovesicles once again underscores curasan AG’s pioneering role when it comes to developing new therapies for musculoskeletal diseases. As the majority shareholder of the newly founded Novaxomx, we have thus set an important course for the successful future of curasan AG,” comments Dirk Dembski, CEO of curasan AG.

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit

About curasan

curasan develops, produces, and markets biomaterials and other medical products in the field of bone and tissue regeneration. As a global technology leader, the German company has specialized in the growth and future market of regenerative medicine, particularly in bio-mimetic bone regeneration materials for use in orthopedics, traumatology, spinal surgery, and dental implantology. These are materials that mimic biological structures. Further information:

Contact Curasan:

Information for journalists: Andrea Weidner, Corporate Communications,

curasan AG

Lindigstraße 4
63801 Kleinostheim
Tel. +49 6027 40900-51
Fax +49 6027 40900-29

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button